Literature DB >> 8396090

A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease.

R B Fitzgeorge1, S Lever, A Baskerville.   

Abstract

The activities of two new macrolides, azithromycin and clarithromycin, were compared in an aerosol-infected guinea-pig model of legionnaires' disease. The results of this study indicate that a low oral dose of azithromycin (3.6 mg/kg) administered once daily gives 100% survival in Legionella pneumophila-infected animals. An eight-fold higher dose of clarithromycin (28.8 mg/kg) given twice-daily was required to achieve the same effect. Similarly, azithromycin was more effective than clarithromycin in preventing pyrexia and in reducing numbers of bacteria and lesions in the lung.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8396090     DOI： 10.1093/jac/31.suppl_e.171

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  12 in total

1.  In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila.

Authors:  Ghislaine Descours; Christophe Ginevra; Nathalie Jacotin; Françoise Forey; Joëlle Chastang; Elisabeth Kay; Jerome Etienne; Gérard Lina; Patricia Doublet; Sophie Jarraud
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

3.  Retrospective analysis of azithromycin versus fluoroquinolones for the treatment of legionella pneumonia.

Authors:  Jerod L Nagel; Rachel E Rarus; Alex W Crowley; Cesar Alaniz
Journal:  P T       Date:  2014-03

4.  In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; T Shinzato; E Doyle; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

5.  Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.

Authors:  J Plouffe; D B Schwartz; A Kolokathis; B W Sherman; P M Arnow; J A Gezon; B Suh; A Anzuetto; R N Greenberg; M Niederman; J A Paladino; J A Ramirez; J Inverso; C A Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

6.  Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study.

Authors:  S Schönwald; I Kuzman; K Oresković; V Burek; V Skerk; V Car; D Bozinović; J Culig; S Radosević
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

7.  Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem.

Authors:  C Ponte; A Parra; E Nieto; F Soriano
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 8.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.

Authors:  Paul H Edelstein; William J Weiss; Martha A C Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs.

Authors:  J García-de-Lomas; E Millás; M A Lázaro; M Bermejo; C Gimeno; D Navarro; S Sánchez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.